First breath of hope: new inhaled therapy enters human testing for cystic fibrosis
Disease control
Recruiting now
This early-stage study is testing a new inhaled medication called RCT2100 for people with cystic fibrosis. The research will first check if the treatment is safe in healthy volunteers, then test it in people with CF who cannot use current standard medications. The goal is to see …
Phase: PHASE2 • Sponsor: ReCode Therapeutics • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC